Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice

Journal of Lipid Research

Volumn 49, Issue 8, 2008, Pages 1677-1681

  Glaros, Elias N ^a   Kim, Woojin S ^a   Rye, Kerry Anne ^b   Shayman, James A ^c   Garner, Brett ^a,d  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Atherosclerosis therapeutics; Glycolipid synthesis inhibition; Glycosphingolipids; Lipidmetabolism; Sphingolipids

Indexed keywords

APOLIPOPROTEIN E; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; DEXTRO THREO ETHYLENDIOXYPHENYL 2 PALMITOYLAMINO 3 PYRROLIDINOPROPANOL; GLYCOSPHINGOLIPID; UNCLASSIFIED DRUG; 3',4' ETHYLENEDIOXYPHENYL 2 PALMITOYLAMINO 3 PYRROLIDINO 1 PROPANOL; 3',4'-ETHYLENEDIOXYPHENYL-2-PALMITOYLAMINO-3-PYRROLIDINO-1-PROPANOL; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLTRANSFERASE; PROPANOLAMINE DERIVATIVE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DRUG ANTAGONISM; FAT INTAKE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIETARY FATS; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; MALE; MICE; PROPANOLAMINES; PYRROLIDINES;

EID: 50649098512     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E800005-JLR200     Document Type: Article

References (21)

1. Dawson, G., A. W. Kruski, and A. M. Scanu. 1976. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J. Lipid Res. 17: 125-131.
2. Breckenridge, W. C., J. L. Halloran, K. Kovacs, and M. D. Silver. 1975. Increase of gangliosides in atherosclerotic human aortas. Lipids. 10: 256-259.
3. Garner, B., D. A. Priestman, R. Stocker, D. J. Harvey, T. D. Butters, and F. M. Platt. 2002. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J. Lipid Res. 43: 205-214.
4. Garner, B., H. R. Mellor, T. D. Butters, R. A. Dwek, and F. M. Platt. 2002. Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein-E levels by glycosphingolipids. Biochem. Biophys. Res. Commun. 290: 1361-1367.
5. Glaros, E. N., W. S. Kim, C. M. Quinn, J. Wong, I. Gelissen, W. Jessup, and B. Garner. 2005. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apoA-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J. Biol. Chem. 280: 24515-24523.
6. Gong, N., H. Wei, S. H. Chowdhury, and S. Chatterjee. 2004. Lactosylceramide recruits PKCalpha/epsilon and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells. Proc. Natl. Acad. Sci. USA. 101: 6490-6495.
7. Bhunia, A. K., H. Han, A. Snowden, and S. Chatterjee. 1997. Redoxregulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J. Biol. Chem. 272: 15642-15649.
8. Prokazova, N. V., I. A. Mikhailenko, and L. D. Bergelson. 1991. Ganglioside GM3 stimulates the uptake and processing of low density lipoproteins by macrophages. Biochem. Biophys. Res. Commun. 177: 582-587.
9. Bodary, P. F., Y. Shen, F. B. Vargas, X. Bi, K. A. Ostenso, S. Gu, J. A. Shayman, and D. T. Eitzman. 2005. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation. 111: 629-632.
10. Park, T. S., R. L. Panek, S. B. Mueller, J. C. Hanselman,W. S. Rosebury, A. W. Robertson, E. K. Kindt, R. Homan, S. K. Karathanasis, and M. D. Rekhter. 2004. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 110: 3465-3471.
11. Hojjati, M. R., Z. Li, H. Zhou, S. Tang, C. Huan, E. Ooi, S. Lu, and X. C. Jiang. 2005. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 280: 10284-10289.
12. Glaros, E. N., W. S. Kim, B. J. Wu, C. Suarna, C. M. Quinn, K. A. Rye, R. Stocker, W. Jessup, and B. Garner. 2007. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem. Pharmacol. 73: 1340-1346.
13. Glaros, E. N., W. S. Kim, C. M. Quinn, W. Jessup, K. A. Rye, and B. Garner. 2008. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J. Lipid Res. 49: 324-331.
14. Kim, W. S., C. E. Chalfant, and B. Garner. 2006. Fine tuning therapeutic targeting of the sphingolipid biosynthetic pathway to treat atherosclerosis. Curr. Vasc. Pharmacol. 4: 151-154.
15. Abe, A., S. Gregory, L. Lee, P. D. Killen, R. O. Brady, A. Kulkarni, and J. A. Shayman. 2000. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 105: 1563-1571.
16. Lee, L., A. Abe, and J. A. Shayman. 1999. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274: 14662-14669.
17. Hojjati, M. R., and X. C. Jiang. 2006. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J. Lipid Res. 47: 673-676.
18. Wing, D. R., B. Garner, V. Hunnam, G. Reinkensmeier, U. Andersson, D. J. Harvey, R. A. Dwek, F. M. Platt, and T. D. Butters. 2001. Highperformance liquid chromatography analysis of ganglioside carbohydrates at the pmol level after ceramide glycanse digestion and fluorescent labelling with 2-aminobenzamide. Anal. Biochem. 298: 207-217.
19. Mukhin, D. N., F. F. Chao, and H. S. Kruth. 1995. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 1607-1615.
20. Park, T. S., R. L. Panek, M. D. Rekhter, S. B. Mueller, W. S. Rosebury, A. Robertson, J. C. Hanselman, E. Kindt, R. Homan, and S. K. Karathanasis. 2006. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in apoE knockout mice. Atherosclerosis. 189: 264-272.
21. Sjogren, B., and P. Svenningsson. 2007. Depletion of the lipid raft constituents, sphingomyelin and ganglioside, decreases serotonin binding at human 5-HT7(a) receptors in HeLa cells. Acta Physiol (Oxf). 190: 47-53.